Ger­man chem­i­cals com­pa­ny to ex­pand its reach in­to mR­NA in­gre­di­ent pro­duc­tion

As the mR­NA field has be­come more pop­u­lar over the past sev­er­al years, thanks in large part to the de­vel­op­ment of cer­tain wild­ly pop­u­lar Covid-19 vac­cines, such as those from Mod­er­na and BioN­Tech, more com­pa­nies are look­ing to sink funds to ac­com­mo­date its pro­duc­tion.

Ger­man chem­i­cal com­pa­ny Wack­er Chemie AG, which has been around since 1914, has been a main­stay in the pro­duc­tion of sil­i­cone-based prod­ucts and oth­er med­i­c­i­nal chem­i­cals, but now its biotech di­vi­sion is look­ing to sink nine fig­ures in­to mR­NA pro­duc­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER